Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,126Revenue (TTM) $M190Net Margin (%)-67.0Altman Z-Score-0.5
Enterprise Value $M1,101EPS (TTM) $-3.5Operating Margin %-61.0Piotroski F-Score3
P/E(ttm)--Beneish M-Score5.0Pre-tax Margin (%)-67.2Higher ROA y-yY
Price/Book42.510-y EBITDA Growth Rate %--Quick Ratio2.9Cash flow > EarningsN
Price/Sales5.05-y EBITDA Growth Rate %--Current Ratio2.9Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-60.0Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M51.3ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with CHRS

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

CHRS is held by these investors:



CHRS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Herman Alan C.Chief Scientific Officer 2017-04-03Sell11,333$20.73-8.1view
Herman Alan C.Chief Scientific Officer 2017-03-01Sell11,333$24.19-21.25view
Herman Alan C.Chief Scientific Officer 2017-02-01Sell11,333$27.37-30.4view
Viret Jean-FredericCFO 2017-01-25Sell3,900$27-29.44view
Herman Alan C.Chief Scientific Officer 2017-01-03Sell11,333$27.95-31.84view
Viret Jean-FredericCFO 2016-12-16Sell3,900$28.3-32.69view
Wahlstrom MatsDirector 2016-12-08Sell53,583$27.52-30.78view
Herman Alan C.Chief Scientific Officer 2016-12-01Sell11,333$27.4-30.47view
Viret Jean-FredericCFO 2016-11-18Sell3,900$28.19-32.42view
Herman Alan C.Chief Scientific Officer 2016-11-01Sell11,333$27.53-30.8view

Press Releases about CHRS :

Quarterly/Annual Reports about CHRS:

News about CHRS:

Articles On GuruFocus.com
Coherus BioSciences to Report First Quarter 2017 Financial Results on May 8th Apr 24 2017 
Coherus BioSciences Appoints Erik Wiberg as Executive Vice President of Corporate Development Mar 27 2017 
Coherus BioSciences Reports Fourth Quarter and Full Year 2016 Corporate Highlights and Financial Res Mar 13 2017 
Coherus Addresses Trade Secret Action Filed by Amgen Mar 06 2017 
Coherus Announces CHS-1420 Pharmacokinetic Clinical Bioequivalence Study Meets Primary Endpoint Mar 02 2017 
Statement by Coherus CEO Regarding Biosimilars User Fees Mar 02 2017 
Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in March Mar 01 2017 
Coherus Biosciences' Humira Petition Denied Nov 08 2016 
A Look at Pharma Company Dermira's Performance Mar 27 2015 

More From Other Websites
Coherus BioSciences to Report First Quarter 2017 Financial Results on May 8th Apr 24 2017
ETFs with exposure to Coherus BioSciences, Inc. : April 5, 2017 Apr 05 2017
Coherus BioSciences Appoints Erik Wiberg as Executive Vice President of Corporate Development Mar 27 2017
Coherus BioSciences, Inc. :CHRS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Mar 20 2017
Coherus BioSciences, Inc. :CHRS-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017 Mar 16 2017
Edited Transcript of CHRS earnings conference call or presentation 13-Mar-17 8:30pm GMT Mar 13 2017
Coherus BioSciences reports 4Q loss Mar 13 2017
Coherus BioSciences Reports Fourth Quarter and Full Year 2016 Corporate Highlights and Financial... Mar 13 2017
Coherus Addresses Trade Secret Action Filed by Amgen Mar 06 2017
Statement by Coherus CEO Regarding Biosimilars User Fees Mar 02 2017
5 Small-Cap Biotech Stocks to Buy in March Mar 02 2017
Coherus Announces CHS-1420 Pharmacokinetic Clinical Bioequivalence Study Meets Primary Endpoint Mar 02 2017
Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in March Mar 01 2017
Coherus BioSciences to Report Fourth Quarter and Full Year 2016 Financial Results on March 13th Feb 21 2017
Coherus BioSciences Announces New Employment Inducement Grants Feb 17 2017
Why Coherus Biosciences Is Falling Today Feb 08 2017
Coherus Biosciences Inc (CHRS) Could Be A Discount Entry On The Pullback Feb 08 2017
Coherus Prices Public Offering of Common Stock Feb 08 2017
Coherus Announces Proposed Public Offering of Common Stock Feb 07 2017
Coherus BioSciences Files Four Petitions for Inter Partes Review Against AbbVie’s HUMIRA®... Jan 31 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)